Agents Used in Antiretroviral Therapy
Summary
- Nevirapine is an NNRTI indicated in combination with other antiretroviral agents
- It can be administered to treatment-naive and treatment-experienced patients, but caution should be employed when initiating nevirapine-based antiretroviral therapy in women with CD4+ cell counts > 250 cells/mm3 or men with CD4+ cell counts > 400 cells/mm3
- Nevirapine should be administered initially at 200 mg once daily (immediate-release formulation) for 14 days; if well tolerated, full dose is 200 mg twice daily (immediate-release) or 400 mg once daily (extended-release)[FDA Nevirapine XR]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content